Cent Eur J Public Health 2026, 34(1):16-21 | DOI: 10.21101/cejph.a8674

Vaccination coverage against COVID-19 among people living with HIV infection in the Czech Republic

Lukáš Fleischhans1, Barbora Králíčková1, Marek Malý2, Ladislav Machala3, David Jilich1
1 Department of Infectious Diseases, First Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
2 National Institute of Public Health, Prague, Czech Republic
3 Department of Infectious Diseases, Third Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic

Objectives: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected hundreds of millions of individuals globally. Vaccination has become a promptly effective preventive procedure. People living with HIV (PLHIV) are in increased risk of many infections including COVID-19. We aimed to analyse the first phase of vaccination (January 2021–June 2022) in the Czech Republic in PLHIV focusing on vaccination coverage, vaccine hesitancy and breakthrough infections.

Methods: In this single-centre, open-label, prospective study we have enrolled 1,758 PLHIV with median age of 42.5 years and median CD4+ T cells count (cluster of differentiation) 800/µL.

Results: Vaccination coverage was 84.7% and first booster dose was received by 71.7% of those who completed vaccination. Only 78 individuals (4.4%) have actively rejected vaccination. The most frequent vaccination scheme (60.3%) was Comirnaty vaccine plus booster of the same vaccine. There was a significant difference between vaccinated and unvaccinated individuals in age, CD4+ count, CD4/CD8 ratio, virological suppression on antiretroviral therapy (ART) duration of HIV and level of education (p < 0.001). Prevalence of breakthrough infection was seen in 21.4%. There was no significant difference among individual vaccines (p = 0.715). Individuals with breakthrough infections were statistically younger (p = 0.001) with some risk factors in 25.1%.

Conclusion: In this prospective study we have seen higher vaccination coverage against COVID-19 in PLHIV in the Czech Republic in comparison with the general Czech population. Hesitancy, resulting in rejection of vaccination, was lower in our cohort as regards affinity to the HIV clinic, and breakthrough infections were noticed and occurred particularly in younger age groups.

Klíčová slova: HIV, COVID-19, vaccination, hesitancy, breakthrough infections

Vloženo: 6. červen 2025; Revidováno: 14. prosinec 2025; Přijato: 14. prosinec 2025; Zveřejněno: 31. březen 2026  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fleischhans L, Králíčková B, Malý M, Machala L, Jilich D. Vaccination coverage against COVID-19 among people living with HIV infection in the Czech Republic. Cent Eur J Public Health. 2026;34(1):16-21. doi: 10.21101/cejph.a8674.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF bude odemčeno 30.9.2026

    Reference

    1. World Health Organization. WHO COVID-19 dashboard [Internet]. Geneva: WHO; 2025 [cited 2025 Nov 17]. Available from: https://data.who.int/dashboards/covid19/cases?n=o.
    2. Institute of Health Information and Statistics of the Czech Republic. [Current diseases - COVID-19. Reports according to regional hygienic service] [Internet]. Prague: IHIS; 2025 [cited 2025 May 24]. Available from: https://onemocneni-aktualne.mzcr.cz/covid-19/prehledy-khs. Czech.
    3. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022 Apr 16;399(10334):1513-36.
    4. Al Oweidat K, Al-Amer R, Saleh MY, Albtoosh AS, Toubasi AA, Ribie MK, et al. Mortality, intensive care unit admission, and intubation among hospitalized patients with COVID-19: a one-year retrospective study in Jordan. J Clin Med. 2023 Apr 2;12(7):2651. doi: 10.3390/jcm12072651. Přejít k původnímu zdroji...
    5. Haider N, Hasan MN, Guitian J, Khan RA, McCoy D, Ntoumi F, et al. The disproportionate case-fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world. IJID Reg. 2023 Mar;6:159-66. Přejít k původnímu zdroji...
    6. Bilinski A, Emanuel EJ. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020 Nov 24;324(20):2100-2. Přejít k původnímu zdroji...
    7. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021 Aug 21;21(1):855. doi: 10.1186/s12879-021-06536-3. Přejít k původnímu zdroji...
    8. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020 Dec;13(12):1833-9. Přejít k původnímu zdroji...
    9. Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, et al.; PISCIS study group. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021 Nov;8(11):e701-10. Přejít k původnímu zdroji...
    10. Wit FWNM, Reiss P, Rijnders B, Rokx C, Roukens A, Brinkman K, et al.; ATHENA cohort study group. COVID-19 in people with HIV in the Netherlands. AIDS.2023 Sep 1;37(11):1671-81. Přejít k původnímu zdroji...
    11. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021 Jan;16(1):63-73. Přejít k původnímu zdroji...
    12. Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci. 2022 Sep 12;29(1):68. doi: 10.1186/s12929-022-00852-9. Přejít k původnímu zdroji...
    13. Saha S, Samanta G, Nieto JJ. Impact of optimal vaccination and social distancing on COVID-19 pandemic. Math Comput Simul. 2022 Oct;200:285-14. Přejít k původnímu zdroji...
    14. Jahn B, Sroczynski G, Bicher M, Rippinger C, Mühlberger N, Santamaria J, et al. Evaluation of a targeted COVID-19 vaccination strategy for Austria - a decision-analytic modeling study. Eur J Public Health. 2021 Oct 20;31 Suppl 3:ckab165.078. doi: 10.1093/eurpub/ckab165.078. Přejít k původnímu zdroji...
    15. Sobczak M, Pawliczak R. COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. Ann Clin Microbiol Antimicrob. 2022 Jul 3;21(1):32. doi: 10.1186/s12941-022-00525-3. Přejít k původnímu zdroji...
    16. Hua Q, Zheng D, Yu B, Tan X, Chen Q, Wang L, et al. Effectiveness of inactivated COVID-19 vaccines against COVID-19 caused by the SARS-CoV-2 Delta and Omicron variants: a retrospective cohort study. Vaccines (Basel). 2022 Oct 19;10(10):1753. doi: 10.3390/vaccines10101753. Přejít k původnímu zdroji...
    17. Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination against SARS-CoV-2: a systematic review of existing strategies and guidelines. Vaccines (Basel). 2021 Apr 1;9(4):326. doi: 10.3390/vaccines9040326. Přejít k původnímu zdroji...
    18. Menza TW, Capizzi J, Zlot AI, Barber M, Bush L. COVID-19 vaccine uptake among people living with HIV. AIDS Behav. 2022 Jul;26(7):2224-8. Přejít k původnímu zdroji...
    19. Lin KY, Wu PY, Liu WD, Sun HY, Hsieh SM, Sheng WH, et al. Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. J Microbiol Immunol Infect. 2022 Jun;55(3):535-9. Přejít k původnímu zdroji...
    20. Touizer E, Alrubayyi A, Rees-Spear C, Fisher-Pearson N, Griffith SA, Muir L, et al. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. Lancet HIV. 2021 Jun;8(6):e317-8. Přejít k původnímu zdroji...
    21. Inzaule SC, Kroeze S, Kityo CM, Siwale M, Akanmu S, Wellington M, et al. Long-term HIV treatment outcomes andassociated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis. AIDS. 2022 Aug 1;36(10):1437-47. Přejít k původnímu zdroji...
    22. Costiniuk CT, Singer J, Langlois MA, Kulic I, Needham J, Burchell A, et al. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open. 2021 Dec 16;11(12):e054208. doi: 10.1136/bmjopen-2021-054208. Přejít k původnímu zdroji...
    23. Institute of Health Information and Statistics of the Czech Republic. [Basic reports - COVID-19: overview of the current situation in the Czech Republic - applied vaccines] [Internet]. Prague: IHIS; 2025 [cited 2025 Nov 17]. Available from: https://onemocneni-aktualne.mzcr.cz/covid-19. Czech.
    24. Czech Statistical Office. Population - quarterly and monthly time series [Internet]. Prague: CSO; 2025 [cited on 2025 Nov 17]. Available from: https://csu.gov.cz/produkty/oby_ts.
    25. National Institute of Public Health. [Trends of evolution and appearance of HIV/AIDS in the Czech Republic in 2022] [Internet]. Prague: NIPH [cited 2025 Nov 17]. Available from: https://szu.cz/wp-content/uploads/2023/02/Trendy-vyvoje-a-vyskyt-HIV-AIDS-v-CR---predbezna-zprava-za-rok-2022.pdf. Czech.
    26. Fulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, et al. COVID-19 vaccination rates in a global HIV cohort. J Infect Dis. 2022 Feb 15;225(4):603-7. Přejít k původnímu zdroji...
    27. Tesoriero JM, Patterson W, Daskalakis D, Chicoine J, Morne J, Braunstein S, et al. Notes from the field: COVID-19 vaccination among persons living with diagnosed HIV infection - New York, October 2021. MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):182-4. Přejít k původnímu zdroji...
    28. Rosenthal EM, Patterson W, Chicoine J, Dorabawila V, Adamashvili N, Rajulu DT, et al. COVID-19 vaccination and hospitalization among persons living with diagnosed HIV in New York State. J Acquir Immune Defic Syndr. 2023 Jun 1;93(2):92-100. Přejít k původnímu zdroji...
    29. Gallè F, Sabella EA, Roma P, Da Molin G, Diella G, Montagna MT, et al. Acceptance of COVID-19 vaccination in the elderly: a cross-sectional study in Southern Italy. Vaccines (Basel). 2021 Oct 21;9(11):1222. doi: 10.3390/vaccines9111222. Přejít k původnímu zdroji...
    30. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021 May;194:245-51. Přejít k původnímu zdroji...
    31. Jilich D, Skrzat-Klapaczyńska A, Fleischhans L, Bursa D, Antoniak S, Balayan T, et al.; ECEE Network Group. National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region. HIV Med. 2022 May;23(5):546-52. Přejít k původnímu zdroji...
    32. Lazarus JV, Wyka K, White TM, Picchio CA, Gostin LO, Larson HJ, et al. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat Med. 2023 Feb;29(2):366-75. Přejít k původnímu zdroji...
    33. Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 vaccine hesitancy among French people living with HIV. Vaccines (Basel). 2021 Mar 24;9(4):302. doi: 10.3390/vaccines9040302. Přejít k původnímu zdroji...
    34. Konieczny M, Sobieraj D, Niezgoda A, Gąska I, Mielnik A, Niemiec M, et al. Attitudes of pregnant women toward vaccination against COVID-19 - a study conducted in Poland in the first quarter of 2022. Cent Eur J Public Health. 2024 Dec;32(4):225-30. Přejít k původnímu zdroji...
    35. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021 Feb 16;9(2):160. doi: 10.3390/vaccines9020160. Přejít k původnímu zdroji...
    36. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO, et al. Hesitant or not? The association of age, gender, and education with potential acceptance of a COVID-19 vaccine: a country-level analysis. J Health Commun. 2020 Oct 2;25(10):799-807. Přejít k původnímu zdroji...
    37. Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. Front Public Health. 2021 Aug 13;9:698111. doi: 10.3389/fpubh.2021.698111. Přejít k původnímu zdroji...
    38. Cvjetković S, Jeremić Stojković V, Piperac P, Djurdjević O, Bjegović-Mikanović V. Determinants of COVID-19 vaccine hesitancy: questionnaire development and validation. Cent Eur J Public Health. 2022 Jun;30(2):99-106. Přejít k původnímu zdroji...
    39. Boschung K, Gill MJ, Krentz HB, Dalere J, Beckthold B, Fonseca K, et al. COVID-19 vaccine uptake among people with HIV: identifying characteristics associated with vaccine hesitancy. Sci Rep. 2023 Nov 23;13(1):20610. doi: 10.1038/s41598-023-47106-8. Přejít k původnímu zdroji...
    40. Coburn SB, Humes E, Lang R, Stewart C, Hogan BC, Gebo KA, et al.; Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA. Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw Open. 2022 Jun 1;5(6):e2215934. doi: 10.1001/jamanetworkopen.2022.15934. Přejít k původnímu zdroji...
    41. Hogarth M, John D, Li Y, Wang-Rodriguez J, Chakladar J, Li WT, et al. Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems. Am J Med Sci. 2023 Aug;366(2):102-13. Přejít k původnímu zdroji...
    42. Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, et al.; Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACORD of IeDEA. Analysis of severe illness after postvaccination COVID-19 breakthrough among adults with and without HIV in the US. JAMA Netw Open. 2022 Oct 3;5(10):e2236397. doi: 10.1001/jamanetworkopen.2022.36397. Přejít k původnímu zdroji...
    43. Yang X, Zhang J, Liu Z, Chen S, Olatosi B, Poland GA, et al. COVID-19 breakthrough infections among people living with and without HIV: a statewide cohort analysis. Int J Infect Dis. 2024 Feb;139:21-7. Přejít k původnímu zdroji...

    Zpět na obsah